Author:
Alvarado-Ibarra Martha,Antonio De la Peña Celaya José,Luz Arana-Luna Luara,Hernández-Ruiz Eleazar,Luis Alvarez Vera José,Eugenia Espitia Ríos María,Manuel Pérez Zúñiga Juan
Abstract
When diagnosed with ALL the age group between 18 and 45 years old (AYA, adolescents and young adults) do not have the good prognosis factors generally observed in children with this diagnosis. For a long time, it was undetermined whether they should be treated with continuous and sustained chemotherapy as children or whether receive sustained chemotherapy, but with longer rest periods like old adults. The medical care of adolescents and young adults with neoplastic diseases, grouped between 15 and 45 years of age, became an emerging research field of treatment in hematological diseases. Outcomes have asses complete response disease-free survival, and overall survival as markers of response, with very poor results reported. Relevant challenges have been identified in the AYA group with ALL that have drawn attention to the need to increase research in this area, particularly in the care of the population under 45 years of age with hematological malignancies.
Reference111 articles.
1. Coustan-Smith E, Behm FG, Sánchez J, Boyett J, Hancock M, Raimondi S. Immunological detection of minimal residual disease in children with acute lymphoblastic leukemia. Lancet.1998;351:550–554
2. Janossy G, Coustan-Smith E, Campana D. The reliability of citoplasmic CD3+ and CD22+ antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. Leukemia. 1989; 3:170–181
3. Mirji G, Bhat J, Kode J, Benavalli S, Sangar M.” Genetic and clinical characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complexo r cryptic karyotypes.” Leu Res.2016;45:33–39
4. Moorman, Anthony V. “New and emerging prognostic and predictive genetic biomerkers in B-cell presursor acute lymphoblastic leukemia. Leu Res. 2016; 45:407–416
5. Aber D, Orazi A, Hasserjian R et al.The 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127: 2391–2405